Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2010 1
2012 1
2013 1
2014 1
2017 1
2018 1
2019 2
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, Vergote I, Parma G, Nøttrup TJ, Lebreton C, Fasching PA, Pisano C, Manso L, Bourgeois H, Runnebaum I, Zamagni C, Hardy-Bessard AC, Schnelzer A, Fabbro M, Schmalfeldt B, Berton D, Belau A, Lotz JP, Gropp-Meier M, Gladieff L, Lück HJ, Abadie-Lacourtoisie S, Pujade-Lauraine E, Ray-Coquard I. Lorusso D, et al. Among authors: schnelzer a. Int J Gynecol Cancer. 2024 Apr 1;34(4):550-558. doi: 10.1136/ijgc-2023-004995. Int J Gynecol Cancer. 2024. PMID: 38129136 Free PMC article. Clinical Trial.
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P. Hauke J, et al. Among authors: schnelzer a. J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12. J Med Genet. 2019. PMID: 30979843
First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT.
Wendler T, Herrmann K, Schnelzer A, Lasser T, Traub J, Kutter O, Ehlerding A, Scheidhauer K, Schuster T, Kiechle M, Schwaiger M, Navab N, Ziegler SI, Buck AK. Wendler T, et al. Among authors: schnelzer a. Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1452-61. doi: 10.1007/s00259-010-1430-4. Epub 2010 Mar 31. Eur J Nucl Med Mol Imaging. 2010. PMID: 20354851 Clinical Trial.
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R. Harter P, et al. Among authors: schnelzer a. PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017. PLoS One. 2017. PMID: 29053726 Free PMC article.
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.
Dötzer K, Schlüter F, Schoenberg MB, Bazhin AV, von Koch FE, Schnelzer A, Anthuber S, Grab D, Czogalla B, Burges A, Werner J, Mahner S, Mayer B. Dötzer K, et al. Among authors: schnelzer a. Cancers (Basel). 2019 Aug 26;11(9):1250. doi: 10.3390/cancers11091250. Cancers (Basel). 2019. PMID: 31455033 Free PMC article.
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.
Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, Gladieff L, Lück HJ, Floquet A, Chevalier-Place A, Schnelzer A, Pignata S, Selle F, Sehouli J, Brocard F, Mangili G, Pautier P, De Giorgi U, Provansal M, Heudel PE. Ray-Coquard I, et al. Among authors: schnelzer a. JAMA Oncol. 2020 Dec 1;6(12):1923-1930. doi: 10.1001/jamaoncol.2020.4574. JAMA Oncol. 2020. PMID: 33030515 Free PMC article. Clinical Trial.
Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix.
Jesinghaus M, Strehl J, Boxberg M, Brühl F, Wenzel A, Konukiewitz B, Schlitter AM, Steiger K, Warth A, Schnelzer A, Kiechle M, Beckmann MW, Noske A, Hartmann A, Mehlhorn G, Koch MC, Weichert W. Jesinghaus M, et al. Among authors: schnelzer a. J Pathol Clin Res. 2018 Apr;4(2):93-102. doi: 10.1002/cjp2.95. Epub 2018 Mar 8. J Pathol Clin Res. 2018. PMID: 29665323 Free PMC article.
Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer.
Bluemel C, Schnelzer A, Okur A, Ehlerding A, Paepke S, Scheidhauer K, Kiechle M. Bluemel C, et al. Among authors: schnelzer a. Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1656-61. doi: 10.1007/s00259-013-2473-0. Epub 2013 Jun 11. Eur J Nucl Med Mol Imaging. 2013. PMID: 23754763
12 results